Cognition PRIORITY AREA
Why Is Cognition a Priority?
Many Parkinson's patients experience some cognitive dysfunction, and some may progress to dementia. An improved understanding of cognitive impairment in Parkinson's disease would help treat people living with this symptom today and help identify those patients at greatest risk for cognitive dysfunction who might benefit from early intervention.
Our Investment in Cognition
The Michael J. Fox Foundation has supported research focused on Parkinson's disease-related cognitive dysfunction and mood disorders, including efforts to better define cognitive phenotypes of the disease. Major efforts in this area include:
- Partnering with the International Parkinson and Movement Disorder Society to validate the diagnostic criteria for mild cognitive impairment in PD.
- Sponsoring a Phase I clinical trial to test a novel drug therapy for cognitive impairment, as part of a landmark partnership with the pharmaceutical company Sanofi.
- Supporting a comparative study of cognitive scales to determine which are the most sensitive for measuring decline and response to treatment.
- Funding additional projects that seek to determine the neuropathological and neurophysiological changes associated with cognitive dysfunction.
Accelerate Your Research
Access Research Tools
Select from pre-clinical models, reagents, research data and more.
Sign-up for Emails
Receive regular updates on funding opportunities and other resources.